Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael W Stewart

Showing results (1-10 of 135) with videos related to

Pageof 14
Sort By:
Inflammation & Allergy Drug Targets|October 18, 2011
Aflibercept (VEGF-TRAP): the next anti-VEGF drugMichael W Stewart
Mayo Clinic Proceedings|January 4, 2012
The expanding role of vascular endothelial growth factor inhibitors in ophthalmologyMichael W Stewart
American Journal of Ophthalmology|March 31, 2009
Managing retained lens fragments: raising the barMichael W Stewart
Retina (Philadelphia, Pa.)|May 6, 2014
To the EditorMichael W Stewart
Retina (Philadelphia, Pa.)|November 30, 2007
Predicted biologic activity of intravitreal bevacizumabMichael W Stewart
Expert Opinion on Drug Metabolism & Toxicology|September 11, 2024
Intraocular drugs: pharmacokinetic strategies and the influence on efficacy and durabilityMichael W Stewart
Ophthalmology|May 4, 2012
Bevacizumab for retinopathy of prematurityMichael W Stewart
Expert Review of Clinical Pharmacology|March 12, 2013
Aflibercept (VEGF Trap-Eye) for the treatment of exudative age-related macular degenerationMichael W Stewart
American Journal of Ophthalmology|September 4, 2007
Management of retained lens fragments: can we improve?Michael W Stewart
Clinical Ophthalmology (Auckland, N.Z.)|September 23, 2015
Visual outcomes of age-related macular degeneration patients undergoing intravitreal ranibizumab monotherapy in an urban population: letter to the editorMichael W Stewart
Pageof 14

Showing results (1-10 of 135) with videos related to

Sort By:
Pageof 14
Inflammation & Allergy Drug Targets|October 18, 2011
Aflibercept (VEGF-TRAP): the next anti-VEGF drugMichael W Stewart
Mayo Clinic Proceedings|January 4, 2012
The expanding role of vascular endothelial growth factor inhibitors in ophthalmologyMichael W Stewart
American Journal of Ophthalmology|March 31, 2009
Managing retained lens fragments: raising the barMichael W Stewart
Retina (Philadelphia, Pa.)|May 6, 2014
To the EditorMichael W Stewart
Retina (Philadelphia, Pa.)|November 30, 2007
Predicted biologic activity of intravitreal bevacizumabMichael W Stewart
Expert Opinion on Drug Metabolism & Toxicology|September 11, 2024
Intraocular drugs: pharmacokinetic strategies and the influence on efficacy and durabilityMichael W Stewart
Ophthalmology|May 4, 2012
Bevacizumab for retinopathy of prematurityMichael W Stewart
Expert Review of Clinical Pharmacology|March 12, 2013
Aflibercept (VEGF Trap-Eye) for the treatment of exudative age-related macular degenerationMichael W Stewart
American Journal of Ophthalmology|September 4, 2007
Management of retained lens fragments: can we improve?Michael W Stewart
Clinical Ophthalmology (Auckland, N.Z.)|September 23, 2015
Visual outcomes of age-related macular degeneration patients undergoing intravitreal ranibizumab monotherapy in an urban population: letter to the editorMichael W Stewart
Pageof 14